You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 81 - 90 of 7423 results
  1. Manganese-based Contrast Agent for Cardiovascular MRI

    SBC: Reveal Pharmaceuticals, Inc.            Topic: NHLBI

    ABSTRACT Cardiovascular disease is the leading cause of morbidity and death, representing 1 in 3 deaths in the United States, and 18.6 million deaths globally annually. Contrast enhanced magnetic resonance imaging (MRI) and computed tomography (CT) play a key role in managing heart disease by enabling non-invasive assessment of myocardial perfusion, infarction, and viability. Cardiac imaging is th ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Autonomous Navigating Robot for Detecting Falls and Risk of Falls in Nursing Home Residents with Alzheimer's Disease /ADRD

    SBC: VIGOROUS MIND INC            Topic: R

    ABSTRACT Between half and three-quarters of nursing home (NH) residents fall each year. About 5% of adults 65 and older live in nursing homes, but nursing home residents account for 20% of deaths from falls in this age group. 50% of nursing home residents have moderate or severe cognitive impairment. Older adults with Alzheimer’s Disease or ADRD are more likely to fall than their peers without c ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A simulation platform to predict dose and therapeutic window of immunocytokines

    SBC: Applied BioMath, LLC            Topic: NIAID

    Project Summary/Abstract Immunocytokines (ICs) are fusion proteins of an engineered cytokine conjugated to an antibody. These novel molecules are the next generation of cytokine-based immunotherapies with potential applications in a diverse range of diseases such as rheumatoid arthritis (RA), psoriasis, and cancer. ICs are designed to selectively target diseased tissue or specific immune cells wit ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Next generation free energy perturbation (FEP)calculations--enabled by a novel integration of quantum mechanics (QM) with molecular dynamics allowing a large QM region and no sampling compromises

    SBC: QUANTUM SIMULATION TECHNOLOGIES INC            Topic: 400

    Project Summary The value of computational chemistry to commercial drug discovery is now well-established. Virtual screening (including molecular docking) now jumpstarts most discovery efforts. More recently, a combination of GPU and cloud based computing has vastly increased the realistic computational throughput available for drug discovery. In turn, this has ignited substantial interest in rela ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Tele-FootX: Virtually Supervised Tele-Exercise Platform for Accelerating Plantar Wound Healing

    SBC: BIOSENSICS LLC            Topic: NIA

    Abstract Foot ulceration is the most common and costly late complication of diabetes, with morbidity and mortality being worse than many cancers. It is estimated that up to one-third of people with diabetes will develop a diabetic foot ulcer (DFU) in their lifetime. Non-healing DFUs are a leading cause of hospitalization, amputation, disability, and death among people with diabetes. In the United ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Dedicated Fluidjet Technology for Single-session Debridement of Necrotizing Pancreatitis

    SBC: HYDROCISION INC            Topic: 300

    Acute pancreatitis results in over 275,000 U.S. hospital admissions and more than $2.5 billion in healthcare cost annually. Pancreatic necrosis occurs in about 20% of patients who have severe acute pancreatitis. One in three of these patients will develop infected pancreatic necrosis, which is associated with mortality rates of 11 -39%. Treatment of infected acute necrotizing pancreatitis is cruci ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Fibrogenesis Targeted Manganese Based MRI Contrast Agent

    SBC: Reveal Pharmaceuticals, Inc.            Topic: 300

    Nonalcoholic fatty liver disease (NAFLD) affects an estimated 20-30% of adults in the western world. Most NAFLD is benign, but up to 30% of NAFLD patients will develop a progressive form of fatty liver termed nonalcoholic steatohepatitis (NASH). NASH is the leading cause of severe liver disease, leading to rt$175 billion in healthcare costs over the next two decades in the US, and NASH prevalence ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Blood-based Test for Identifying Synucleinopathy in Patients with Dementia

    SBC: Neurodex Inc            Topic: NINDS

    PROJECT SUMMARY In this Fast Track SBIR application, NeuroDex, Inc. proposes to use its expertise in extracellular vesicle (EV) immunoaffinity isolation to develop a blood test that detects synucleinopathies with high sensitivity, with the long- term goal of helping clinicians identify patients for whom antipsychotic drugs are harmful and contraindicated. Development and commercialization of a sen ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Combination Therapeutic for Chronic Opioid Use Disorder Relapse

    SBC: APHIOS CORPORATION            Topic: NIDA

    PROJECT SUMMARY Few therapeutics are available for individuals trying to recover from opioid use disorder. Buprenorphine and methadone, opioid receptor agonists, are approved by the FDA to treat Opioid Use Disorder (OUD) but long- term efficacy and treatment adherence are sub-optimal. Extended-release naltrexone (Vivitrol®, Alkermes), a full µ-opioid receptor antagonist, was approved by the FDA ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Gene-edited liver organoids for predictive hepatotoxicity

    SBC: Bioprinting Laboratories Inc.            Topic: R

    Project Summary/Abstract Unexpected adverse drug responses (ADRs) including drug-induced liver injury (DILI) are the 4th leading cause of death in the U.S. In addition, DILI in individuals is one of the major reasons for drug withdrawal from the market and is difficult to predict using conventional in vitro hepatotoxicity tests and preclinical animal models. Due to the critical link between DILI a ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government